Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG4 + PA-002
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PG4 + PA-002 is an experimental vaccine combination developed by Pfizer for the prevention of Streptococcus pneumoniae infections. It consists of PG4, a multivalent pneumococcal conjugate vaccine, and PA-002, which serves as an adjuvant or specialized formulation component. The vaccine is designed to provide broad protection against pneumococcal disease by inducing an immune response against multiple bacterial serotypes. It is currently being evaluated in Phase 1 clinical trials to determine the safety, tolerability, and immunogenicity of different dosage levels of PA-002 when combined with the PG4 vaccine in healthy adults.
Beyond the preview
Go deeper on PG4 + PA-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG4 + PA-002.